Core Insights - The company has selected ASC36 as a clinical development candidate, which is expected to be a best-in-class monthly subcutaneous injection amylin receptor agonist for obesity treatment [1][2] - ASC36 is developed using the company's AI-assisted drug discovery and ultra-long-acting drug development platforms, featuring optimized properties for longer half-life and higher bioavailability [1] - The company plans to submit an Investigational New Drug (IND) application to the FDA in Q2 2026 [1] Drug Development and Efficacy - ASC36 has an observed half-life of approximately 15 days in non-human primate studies, which is three times longer than petrelintide, supporting the potential for monthly dosing in humans [2] - In diet-induced obesity rat studies, ASC36 demonstrated a weight reduction of 10.01%, compared to 5.25% for petrelintide, indicating a 91% relative improvement in weight loss efficacy [2] - The optimized characteristics of ASC36 may lead to lower manufacturing costs and improved dosing regimens for patients [2]
歌礼制药-B(01672.HK)：选定同类最佳每月一次皮下注射胰淀素受体激动剂ASC36进入临床开发阶段